Objective The aim of this study was to evaluate the effectiveness and safety of percutaneous interstitial implantation with 125I seed under computed tomographic (CT) guidance for recurrent ovarian cancer (ROC).
Materials and Methods A retrospective review was performed on 17 patients with ROC who were treated with 125I seed brachytherapy. Treatment planning system was used preoperatively to determine the estimated seeds number and distribution; 125I seeds were implanted into recurrent lesions under CT guidance. Therapeutic effectiveness and complications were noted during follow-up time.
Results Months are counted from the time of 125I seed brachytherapy, and the median duration of follow-up was 10.5 months (3-23 months). The objective response rates after 1, 3, 6, 12, and 18 months were 76.5%, 75.0%, 61.5%, 42.9%, and 40%, respectively. The pain relief rate was 61.5%, and the general living quality was improved dramatically. The median progression-free survival time was 5.4 months, the median overall survival time was 11.3 months, and the 1-year survival rate was 41.2%. Complications in this study were very mild; severe adverse events such as massive bleeding, intestinal fistula, and treatment-related deaths did not occur.
Conclusions Our initial experience showed that CT-guided 125I seed interstitial implantation is safe and feasible in the treatment of patients with ROCs after multiple therapies.
- 125I seed
- Recurrent ovarian cancer
Statistics from Altmetric.com
The authors declare no conflicts of interest.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.